SAVANNAH, GA--(INFOLINK)--Mar 28, 2005--Health Discovery Corporation (OTC BB: HDVY) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application covering "The method for the manipulation, storage, modeling, visualization and quantification of datasets using a proprietary adaptation of the fractal analysis." This is the base patent application and the first of a series of patent applications covering the Fractal Genomics Modeling (FGM) technology. The FGM technology can be applied to genomic analysis to identify biomarkers to develop treatments, diagnoses or prognoses of diseases by exploiting the map of interactions and the causal relationships between genes rendered by this technology.
In addition to this allowed patent application for our Fractal Genomics Modeling (FGM) technology, Health Discovery Corporation's patent portfolio includes 10 issued U.S. and foreign patents covering among other things; applications of our support vector machine (SVM) technology and Recursive Feature Elimination (RFE) technology used in Support Vector Machines for biomarker discovery. The issued patents cover methods and systems for pre-processing data to enhance knowledge discovery using SVMs, analysis of data using multiple support vector machines and for multiple data sets, and providing SVM analysis services over the Internet while collecting financial compensation electronically in the process.
In addition, Health Discovery Corporation has over 65 pending patent applications for various techniques used in biomarker discovery as well as for newly discovered biomarkers. HDC's pending U.S. and foreign patent applications cover numerous improvements to and applications of FGM techniques and SVM techniques, including computer-aided image analysis using SVMs, with particular application to diagnosis using medical images of digital mammography for breast cancer and images of blood for the identification of circulating tumor cells, methods of feature selection for enhanced SVM efficiency and new biomarkers discovered for colon cancer, prostate cancer, leukemia and renal cancer using these methods, as well as the use of SVMs for analysis of spectral data such as data generated in mass spectrometry.
The original scientific publication introducing Recursive Feature Elimination (RFE) in Support Vector Machines (SVMs) was co-authored by Health Discovery Corporation's Chairman and CEO, Dr. Stephen D. Barnhill, and two members of Health Discovery Corporation's Scientific Team -- Dr. Vladimir Vapnik and Dr. Isabelle Guyon. This original paper can be read at http://www.kyb.tuebingen.mpg.de/bs/people/weston/GENESEL.PDF.
Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation, commented, "I am thrilled that the United States Patent and Trademark Office has issued a Notice of Allowance for the first in a series of patent applications covering our Fractal Genomics Modeling (FGM) technology which has been shown to be a very important tool for proteomic and genomic biomarker discovery. FGM is a great addition to the Company's patented Support Vector Machine technology which is also critical to our biomarker discovery efforts." Dr. Barnhill continued, "This Notice of Allowance further solidifies our position as a leader in biomarker discovery, which is considered to be a very important aspect of the personalized medicine process recently described in the Food and Drug Administration (FDA) final guidance titled 'Pharmacogenomic Data Submissions' released March 22, 2005, as part of an agency-wide initiative to speed development of new medical products through the science of pharmacogenomics."
Janet Woodcock, M.D., Acting Deputy Commissioner for Operations, FDA, explained that 'personalized medical treatment' is now one step closer, further stating, "This new technology will allow medicines to be uniquely crafted to maximize their therapeutic benefits and minimize their potential risks for each patient."
The FDA's Press Release stated: "Instead of the standard hit-or-miss approach to treating patients, where it can take multiple attempts to find the right drug and the right dose, doctors will eventually be able to analyze a patient's genetic profile and prescribe the best available drug therapy and dose from the start. Both the guidance and a new Web page are part of a broad effort underway at FDA to foster pharmacogenomics during drug development."
"We hope ultimately to bring pharmacogenomics, a way in which to foster the personalizing of medicine, to every healthcare professional's prescription pad for the benefit of their patients and U.S. consumers," said Dr. Woodcock.
The FDA Guidance for Industry: Pharmacogenomic Data Submissions released on 3/22/2005 can be read in its entirety at http://www.fda.gov/cber/gdlns/pharmdtasub.pdf
Health Discovery Corporation is a systems biology-oriented biomarker and pathway discovery company, which provides all aspects of First-Phase Biomarker Discovery(SM). The Company was established to provide pharmaceutical and diagnostic companies worldwide with newly discovered biomarkers used to create more accurate diagnostic tests, novel drug targets for more personalized medicines and new methods for detecting patients "at-risk" for toxicity-related events, thereby providing safer medications. Founded in September 2003, the Company is headquartered in Savannah, GA. For more information contact: Stephen D. Barnhill, M.D. of Health Discovery Corporation, 1-800-965-3198 or barnhillmd@sprynet.com.
This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.
CONTACT: Stephen D. Barnhill, M.D.
800-965-3198
barnhillmd@sprynet.com
http://www.healthdiscoverycorp.com
